Swiss National Bank Purchases 40,700 Shares of Cellebrite DI Ltd. $CLBT

Key Points

• Swiss National Bank expanded its stake in Cellebrite DI Ltd. by 27% in Q1, holding 191,300 shares valued at approximately $3.72 million.
• Cellebrite DI's stock experienced a 52-week range between $13.10 and $26.30, and opened at $15.48 on Thursday.
• The company reported Q2 earnings with an EPS of $0.12, surpassing the expected $0.11, alongside revenue growth of 18.4% year-over-year.

Swiss National Bank lifted its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 27.0% during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 191,300 shares of the company's stock after buying an additional 40,700 shares during the period. Swiss National Bank owned approximately 0.08% of Cellebrite DI worth $3,717,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of CLBT. Assetmark Inc. purchased a new position in shares of Cellebrite DI in the 1st quarter worth approximately $33,000. Catalyst Capital Advisors LLC bought a new stake in shares of Cellebrite DI in the 1st quarter worth approximately $51,000. Gen Wealth Partners Inc bought a new stake in shares of Cellebrite DI in the 4th quarter worth approximately $85,000. NewEdge Advisors LLC raised its holdings in shares of Cellebrite DI by 600.7% in the 4th quarter. NewEdge Advisors LLC now owns 3,910 shares of the company's stock worth $86,000 after purchasing an additional 3,352 shares during the period. Finally, Sigma Planning Corp bought a new stake in shares of Cellebrite DI in the 1st quarter worth approximately $233,000. Hedge funds and other institutional investors own 45.88% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on CLBT. JPMorgan Chase & Co. lowered their price target on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating on the stock in a report on Monday, May 12th. Wall Street Zen raised shares of Cellebrite DI from a "hold" rating to a "buy" rating in a report on Saturday, August 16th. Needham & Company LLC lowered their price target on shares of Cellebrite DI from $24.00 to $18.00 and set a "buy" rating on the stock in a report on Thursday, August 14th. Finally, Lake Street Capital lowered their price target on shares of Cellebrite DI from $24.00 to $22.00 and set a "buy" rating on the stock in a report on Friday, August 15th. Five investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $22.40.

Cellebrite DI Trading Down 0.2%

Shares of Cellebrite DI stock traded down $0.03 during trading on Tuesday, hitting $15.80. The stock had a trading volume of 1,408,205 shares, compared to its average volume of 2,315,374. The firm has a market cap of $3.78 billion, a price-to-earnings ratio of -20.79, a P/E/G ratio of 3.14 and a beta of 1.27. Cellebrite DI Ltd. has a 12 month low of $13.10 and a 12 month high of $26.30. The business's 50-day moving average is $14.94 and its 200 day moving average is $17.34.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its quarterly earnings results on Thursday, August 14th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.01. The firm had revenue of $113.28 million for the quarter, compared to analysts' expectations of $112.33 million. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The business's quarterly revenue was up 18.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.10 earnings per share. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities analysts expect that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.